Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.

Fiche publication

Date publication

juillet 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François

Tous les auteurs :
Dasari A, Eng C, Lonardi S, Garcia-Carbonero R, Masuishi T, Cremolini C, Ghiringhelli F, Hubbard J, Bekaii-Saab T, Jones J, Xu RH, Shen L, Xu J, Bai Y, Deng Y, Yuan Y, Wei W, Lin J, Chen L, Yang Z, Schelman WR, Qin S, Li J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40795524

Résumé

In the phase 3 FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) studies, fruquintinib vs placebo, plus best supportive care, significantly improved overall survival (OS) in patients with metastatic colorectal cancer (mCRC). These studies were conducted in temporally and geographically diverse populations that received distinct prior therapies; FRESCO patients were less pretreated than FRESCO-2 patients. This analysis assessed the efficacy and safety of fruquintinib in a less pretreated global population than the FRESCO-2 intention-to-treat (ITT) population.